|Dataset type:||Expression profiling by high throughput sequencing|
|Number of samples:||18|
|Release date:||Feb 15 2019|
|Last update date:||Feb 15 2019|
|Dataset link||Single-Dose CRISPR/Cas9 Therapy Extends Lifespan of Mice with Hutchinson-Gilford Progeria Syndrome|
Gene expression analyses of (1) Pro/Pro;Cas9/+ (2) Pro/+; +/+ (3) +/+;Cas9/+ primary mouse fibroblasts treated with a mock gRNA or Lmna target gRNA1, or Lmna target gRNA2. Each treatment was performed on fibroblast cells isolated from 2 different mice (2 biological replicates). The gRNAs were delivered into the cells by Lentiviral vectors that carried the mCherry gene as a reporter; no selection or sorting was performed post-treatment, however each sample was more than 80% mCherry-positive based on fluorescence microscopy. mock gRNA (a gRNA with no match on the genome) treatment was used as a negative control. Likewise, no transgenic Cas9 background (Pro/+; +/+) was used as another negative control.